Crémieux: Viagra for Life Extension Does It Work? I'm Doubtful

Key Takeaways

• Two 2025 MR studies show conflicting links between PDE5 inhibition and dementia
• One study reports increased AD risk (OR 1.09) and LBD risk (OR 1.32)
• The other finds no causal effect of PDE5 inhibitors on Alzheimer’s incidence
• Community reports ocular adverse events rise up to 2.58‑fold with regular use
• Evidence remains insufficient to endorse Viagra for neurodegenerative disease prevention

Pulse Analysis

Mendelian‑randomisation (MR) offers a genetic proxy to test drug effects without exposing patients to experimental therapies. The two 2025 MR papers on phosphodiesterase‑5 (PDE5) inhibition illustrate the method’s power and its limits. While one study observed a slight uptick in Alzheimer’s odds and a notable rise in Lewy‑body dementia risk, the other concluded that PDE5 inhibitors likely have no causal impact on Alzheimer’s incidence. This divergence stems from differences in instrument selection, statistical thresholds, and the handling of pleiotropy, underscoring that MR results must be interpreted alongside traditional epidemiology.

Beyond the genetics, real‑world data on Viagra’s safety profile adds another layer of complexity. Community comments cite a 1.85‑fold increase in composite ocular adverse events, with retinal detachment and optic neuropathy climbing above two‑fold. Such risks, though relatively rare, could offset any marginal cardiovascular benefits that PDE5 inhibitors provide. Clinicians therefore face a trade‑off: modest heart‑health gains versus heightened eye‑related complications, especially for patients considering long‑term, off‑label use for longevity.

For investors and drug developers, the mixed MR findings dampen enthusiasm for a blockbuster repurposing strategy. The Alzheimer’s market remains lucrative, but the lack of clear genetic support suggests that further large‑scale clinical trials would be high‑risk and costly. Meanwhile, the potential signal of increased Lewy‑body dementia risk warrants close monitoring. Until more definitive evidence emerges, the prudent approach is to reserve PDE5 inhibitors for approved indications—erectile dysfunction and pulmonary hypertension—while continuing to explore safer, targeted neuroprotective therapies.